Trial will evaluate IDE161, IDEAYA s investigational PARG inhibitor, in combination with KEYTRUDA® , Merck s anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer Potential.
Boone Capital Management LLC lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 15.0% during the third quarter, Holdings Channel.com reports. The fund owned 570,682 shares of the company’s stock after purchasing an additional 74,249 shares during the period. IDEAYA Biosciences accounts for about 4.9% of Boone Capital Management LLC’s […]
Boone Capital Management LLC lifted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 15.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 570,682 shares of the company’s stock after purchasing an additional 74,249 shares during the period. […]
IDEAYA Biosciences (NASDAQ:IDYA – Free Report) had its price objective boosted by JPMorgan Chase & Co. from $51.00 to $57.00 in a report issued on Friday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. Several other research analysts have also weighed in on the company. Royal Bank of Canada […]
IDEAYA Biosciences, Inc (NASDAQ:IDYA) Given Average Rating of Buy by Analysts themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.